In recognition of BIO’s 25th anniversary, BIO CEO and President, Jim Greenwood sat down with two early champions to talk about what triggered the formation of the organization and what we can learn from the past to help shape the future. That future is envisioned by BIO’s current chair, Dr. John Maraganore in a third video.
First up is Fred Frank, the first life sciences specialist in investment banking. In a career spanning nearly 60 years, Frank served as the lead underwriter in more than 125 initial public offerings. He negotiated more than 75 mergers and acquisitions, including some of the largest and most important transactions in the history of biotechnology.
Next Greenwood looks back to 1993—the year BIO was established—with Robert Beckman, one of the founding members. Beckman is currently a managing partner at The Channel Group which provides management consulting services to life sciences companies.
After talking about where BIO came from, Greenwood talked about where we are going with Dr. John Maraganore, BIO’s current chair and CEO of Alnylam Pharmaceuticals, Inc. Maraganore has led a career pursuing therapies to address unmet medical needs. At Alnylam Pharmaceuticals, Maraganore is helping lead the development of RNAi therapeutics which aim to address genetic medicines, cardio-metabolic diseases and hepatic infectious diseases.